ecancermedicalscience

Short Communication

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy

28 Feb 2017
Herman Andrés Perroud, O Graciela Scharovsky, Viviana Rosa Rozados, Carlos María Alasino

Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, doses of chemotherapeutic drugs with therapeutic efficacy and low toxicity. This is an effective and low-cost way to treat several types of tumours, including ovarian cancer. Here, we present six cases of advanced ovarian cancer treated with MCT with low doses of cyclophosphamide, which showed clinical response and stable disease.

Related Articles

Marco Aurélio Bertúlio das Neves, Noemi Dreyer Galvão, Fernanda Cristina da Silva de Lima, Júlio Fernando Pinto Oliveria, Sancho Pedro Xavier, Ageo Mário Cândido da Silva
Parth Sharma Harsh Thakkar, Aryan Patil, Preeti Chauhan, Priya Chembon, Shalini Arora Joseph, Smriti Rana, Raj Kalady, Vidhi Wadhwani, Gaurav Urs, Padmavathy Krishna, Rontu Sangma, Rajendra Dutt Bijalwan, Sunanda Samal, Lalit Selvaraju, Syed Mohammad Askari Naqvi, Jatin Bhukal, Johnsurya John, Muttacaud Ramakrishnan Rajagopal, Siddhesh Zadey
Raul Puente-Vallejo, Alex García-Gutiérrez, Sebastián Jara-Jimenez, Martina Natalia Mosquera-Ruiz, Wilmer Tarupi
Yousef Roosta, Hero Khezri, Vahid Hoseinpour, Mohamad Jebraeily, Amirhossein Rayegani, Saeed Razavi-Dizaji